Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Ca

Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT06734702 by Sun Yat-sen University, with a registry enrolment figure of 497 participants, started 2024-11-30 and due to reach its primary completion in 2028-11-29. Interventions recorded: Neoadjuvant therapy; Hypo-RT and concurrent chemotherapy; CFRT and concurrent chemotherapy; Consolidative immunotherapy. Conditions listed: Neoadjuvant Therapy; Concurrent Chemoradiotherapy; Immunotherapy; Locally Advanced Non-Small Cell Lung Cancer. Primary outcome: Progression-Free Survival rate. Lung eligibility wording from the registry: "* Diagnosis: Patients must have locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC), with histological or cytological confirmation of the diagnosis". Sites: China. No results are recorded here; the registry entry is the source.